Cytokinetics, Incorporated

BIT:1CYTK Stock Report

Market Cap: €8.8b

Cytokinetics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BIT:1CYTK Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
13 Jul 26Sell€719Robert BlumIndividual10€71.94
01 Jul 26Sell€559,198Robert BlumIndividual7,500€74.56
15 Jun 26Sell€455,471Robert BlumIndividual7,500€60.73
01 Jun 26Sell€318,803B. ParshallIndividual5,000€63.76
01 Jun 26Sell€192,084Edward KayeIndividual2,933€65.49
27 May 26Sell€497,831Robert BlumIndividual7,500€66.38
14 May 26Sell€500,655Robert BlumIndividual7,500€66.75
05 May 26Sell€1,570,092Sung LeeIndividual23,906€65.68
29 Apr 26Sell€382,313Robert BlumIndividual7,500€50.98
15 Apr 26Sell€415,375Robert BlumIndividual7,500€55.38
15 Apr 26Sell€416,589Andrew CallosIndividual7,449€55.93
01 Apr 26Sell€430,363Robert BlumIndividual7,500€57.38
31 Mar 26Sell€205,147Andrew CallosIndividual3,639€56.37
18 Mar 26Sell€564,726Andrew CallosIndividual10,472€53.94
17 Mar 26Sell€648,611Fady MalikIndividual12,033€53.90
17 Mar 26Sell€1,972,893Robert BlumIndividual36,601€53.90
17 Mar 26Sell€266,010Sung LeeIndividual4,935€53.90
16 Mar 26Sell€90,846Andrew CallosIndividual1,709€53.16
09 Mar 26Sell€152,260Fady MalikIndividual2,907€52.38
09 Mar 26Sell€135,238Andrew CallosIndividual2,582€52.38
09 Mar 26Sell€415,403Robert BlumIndividual7,931€52.38
02 Mar 26Sell€262,040B. ParshallIndividual5,000€52.41
02 Jan 26Sell€48,264Andrew CallosIndividual913€52.86
29 Dec 25Sell€96,033Andrew CallosIndividual1,809€53.09
01 Dec 25Sell€123,542Robert HarringtonIndividual2,150€57.46
19 Nov 25Sell€280,540B. ParshallIndividual5,000€56.11
30 Oct 25Sell€271,807Robert BlumIndividual5,000€54.36
06 Oct 25Sell€346,188Edward KayeIndividual6,757€51.23
01 Oct 25Sell€234,651Robert BlumIndividual5,000€46.93
30 Sep 25Sell€314,295Edward KayeIndividual6,695€46.94
15 Sep 25Sell€211,572Robert BlumIndividual5,000€42.31
02 Sep 25Sell€209,083Robert BlumIndividual5,000€41.82
02 Sep 25Sell€89,740Robert HarringtonIndividual2,150€41.74
02 Sep 25Sell€289,697Edward KayeIndividual6,756€42.88

Insider Trading Volume

Insider Buying: 1CYTK insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 1CYTK?
Owner TypeNumber of SharesOwnership Percentage
State or Government37,5060.0244%
Individual Insiders577,1290.375%
Institutions153,307,86799.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.

Top Shareholders

Top 25 shareholders own 76.63% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.5%
BlackRock, Inc.
20,094,362€1.3b21.4%0.02%
13.7%
T. Rowe Price Group, Inc.
19,108,161€1.2b-2.74%0.11%
5.76%
Wellington Management Group LLP
8,009,489€508.6m0.91%0.09%
4.67%
State Street Investment Management
6,494,233€412.4m13%0.01%
4.52%
Vanguard Capital Management, LLC
6,288,256€399.3m0%0.01%
4.2%
Vanguard Portfolio Management, LLC
5,843,782€371.1m0%0.02%
3.77%
FMR LLC
5,238,550€332.6m-51.1%0.02%
2.67%
Geode Capital Management, LLC
3,712,501€235.7m15.5%0.01%
2.4%
Avoro Capital Advisors LLC
3,333,333€211.7m0%2.55%
2.34%
Capital Research and Management Company
3,247,178€206.2m37.7%0.01%
2.2%
Bank of America Corporation
3,053,108€193.9m6.99%0.05%
1.96%
RTW Investments, LP
2,721,158€172.8m0%1.64%
1.67%
UBS Asset Management AG
2,317,909€147.2m69.6%0.01%
1.19%
Polar Capital Holdings Plc
1,661,248€105.5m-31.4%0.27%
1.15%
William Blair Investment Management, LLC
1,603,442€101.8m47.4%0.15%
1.15%
Integral Health Asset Management, LLC
1,600,000€101.6m14.3%5.43%
1.07%
Paradigm Biocapital Advisors LP
1,480,857€94.0m0%2.17%
1.04%
Northern Trust Global Investments
1,441,634€91.5m4.41%0.01%
1.03%
The Goldman Sachs Group, Inc.
1,434,483€91.1m0%0.03%
1%
Charles Schwab Investment Management, Inc.
1,397,045€88.7m0%0.01%
1%
JP Morgan Asset Management
1,385,699€88.0m91%0.01%
0.99%
Deep Track Capital, LP
1,374,320€87.3m-58.8%1.5%
0.94%
Principal Global Investors, LLC
1,311,664€83.3m20%0.04%
0.87%
Morgan Stanley
1,203,887€76.4m20%0.01%
0.85%
Susquehanna International Group, LLP
1,177,380€74.8m14.1%0.08%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/14 01:46
End of Day Share Price 2026/08/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cytokinetics, Incorporated is covered by 37 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Emily FieldBarclays
Huidong WangBarclays